These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 17202130)

  • 1. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.
    Popa C; Netea MG; van Riel PL; van der Meer JW; Stalenhoef AF
    J Lipid Res; 2007 Apr; 48(4):751-62. PubMed ID: 17202130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.
    Cugno M; Ingegnoli F; Gualtierotti R; Fantini F
    Curr Vasc Pharmacol; 2010 Mar; 8(2):285-92. PubMed ID: 19485909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in serum adipokines profile and insulin resistance in patients with rheumatoid arthritis treated with anti-TNF-
    Corrado A; Colia R; Rotondo C; Sanpaolo E; Cantatore FP
    Curr Med Res Opin; 2019 Dec; 35(12):2197-2205. PubMed ID: 31397188
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
    Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
    Avouac J; Allanore Y
    Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis.
    Pašková U
    Ceska Slov Farm; 2019; 68(6):219-228. PubMed ID: 31906689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy.
    Maruotti N; d'Onofrio F; Cantatore FP
    Clin Exp Med; 2015 Nov; 15(4):433-8. PubMed ID: 25427620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
    LaDuca JR; Gaspari AA
    Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory status and insulin resistance.
    Grimble RF
    Curr Opin Clin Nutr Metab Care; 2002 Sep; 5(5):551-9. PubMed ID: 12172480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice.
    Brånén L; Hovgaard L; Nitulescu M; Bengtsson E; Nilsson J; Jovinge S
    Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2137-42. PubMed ID: 15345516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders.
    Tougaard P; Zervides KA; Skov S; Hansen AK; Pedersen AE
    Immunopharmacol Immunotoxicol; 2016; 38(1):29-38. PubMed ID: 26810853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha interferes with lipid homeostasis and activates acute and proatherogenic processes.
    Fon Tacer K; Kuzman D; Seliskar M; Pompon D; Rozman D
    Physiol Genomics; 2007 Oct; 31(2):216-27. PubMed ID: 17566076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade].
    Ursini F
    Reumatismo; 2009; 61(4):254-9. PubMed ID: 20143002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus.
    Zinman B; Hanley AJ; Harris SB; Kwan J; Fantus IG
    J Clin Endocrinol Metab; 1999 Jan; 84(1):272-8. PubMed ID: 9920095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis.
    Peters MJ; van Sijl AM; Voskuyl AE; Sattar N; Smulders YM; Nurmohamed MT
    Curr Pharm Des; 2012; 18(11):1502-11. PubMed ID: 22364134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control.
    Pedersen BK
    Essays Biochem; 2006; 42():105-17. PubMed ID: 17144883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis.
    Paleolog E
    Mol Pathol; 1997 Oct; 50(5):225-33. PubMed ID: 9497911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.